Eversept Partners’s GSK GSK Stock Holding History

Eversept Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,093,700	Closed	-$73.6M	–	70
2022 Q4	$73.6M	Hold	2,093,700	–	–	6.44%	5
2022 Q3	$61.6M	Buy	2,093,700 +850,740	+68%	+$32.2M	5.34%	6
2022 Q2	$67.6M	Hold	1,242,960	–	–	4.81%	7
2022 Q1	$67.7M	Buy	1,242,960 +40,000	+3%	+$2.17M	5.2%	3
2021 Q4	$66.3M	Hold	1,202,960	–	–	4.24%	5
2021 Q3	$57.5M	Buy	1,202,960 +80,000	+7%	+$4.02M	3.97%	7
2021 Q2	$55.9M	Buy	1,122,960 +199,680	+22%	+$9.59M	3.73%	9
2021 Q1	$41.2M	Buy	923,280 +641,200	+227%	+$29.1M	3.1%	8
2020 Q4	$13M	Buy	+282,080	New	+$13M	1.52%	21

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Eversept Partners's GSK Position: Q1 2026 in Review

Eversept Partners reduced its GSK (GSK) stake by 33% in Q1 2026, selling an estimated $48.5M and leaving 1,785,175 shares worth $98.5M. The position accounts for 5.2% of the portfolio, ranked #4.

Eversept Partners first reported a position in GSK in Q1 2018 and has held it in 33 quarters since. The position peaked at $166M in Q3 2024. 1,032 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Eversept Partners held 1,785,175 shares of GSK worth $98.5M as of Q1 2026.
Eversept Partners sold 894,546 GSK shares in Q1 2026, an estimated $48.5M.
GSK made up 5.2% of Eversept Partners's portfolio in Q1 2026, its #4 holding.
Eversept Partners first reported a position in GSK in Q1 2018 and has held it in 33 quarters since.
Eversept Partners's GSK position peaked at $166M in Q3 2024.
1,032 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.